Facebook Linkedin RSS Twitter Youtube
Home 2021

Retinitis pigmentosa

In a First, Optogenetics Leads to Partial Recovery of Vision for Blind Patient
News

In a First, Optogenetics Leads to Partial Recovery of Vision for Blind Patient

AGTC Proves a Durable Competitor in Gene Therapy for X-Linked Retinitis Pigmentosa
Drug Discovery

AGTC Proves a Durable Competitor in Gene Therapy for X-Linked Retinitis Pigmentosa

AGTC Sets Sights on Late-Stage Retinitis Pigmentosa Gene Therapy Trial
Drug Discovery

AGTC Sets Sights on Late-Stage Retinitis Pigmentosa Gene Therapy Trial

AGTC Plans Pivotal Trial for XLRP Gene Therapy
GEN Edge

AGTC Plans Pivotal Trial for XLRP Gene Therapy

Vision Loss Sees New Therapy through Calming Hyperactive Eye Cells
Featured

Vision Loss Sees New Therapy through Calming Hyperactive Eye Cells

Allergan Buys RetroSense Therapeutics for $60M+
Industry News

Allergan Buys RetroSense Therapeutics for $60M+

CRISPR Fixes Stem Cells Harboring Blindness-Causing Defect
Genome Editing

CRISPR Fixes Stem Cells Harboring Blindness-Causing Defect

Gene Therapy Halts Blindness due to Retinitis Pigmentosa
Genome Editing

Gene Therapy Halts Blindness due to Retinitis Pigmentosa

Spark, Genable Launch Gene Therapy Collaboration
Genome Editing

Spark, Genable Launch Gene Therapy Collaboration

RetroSense Licenses Gene Therapy for Restoring Vision from Wayne State University
Genome Editing

RetroSense Licenses Gene Therapy for Restoring Vision from Wayne State University

123Page 2 of 3
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.